Merck (NYSE:MRK) has taken a significant equity stake in Eikon Therapeutics, expanding its presence in oncology-focused ...

Future AI-guided genomic analysis offers the potential to further optimize gene constructs, expression profiles, and performance traits, accelerating the development of next-generation materials.

The recent presentation of the long-term results of the JCOG0802 phase 3 trial has sparked discussion within the international thoracic surgical community. Initial 5-year results in 2022 reported a ...

From innovative medical devices to breakthrough therapies, these healthcare leaders are positioned to deliver strong returns for investors. BTIG analysts have identified their top healthcare picks ...

Ambry Genetics, part of Tempus AI, contributed to research using advanced genetic assays to refine how hereditary cancer ...

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics.

The Precision Medicine market is expanding via advancements in genomic sequencing, AI-driven analytics, and collaborative global genomics programs. Key trends include companion diagnostics in oncology ...

Detailed price information for Davita Healthcare Partners Inc (DVA-N) from The Globe and Mail including charting and trades.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago. These ...

Palantir stock sold off sharply on Wednesday giving back gains from its Q4 earnings report amid volatility in artificial ...

Twist Bioscience's Q1 growth was modest, due in large part to an air pocket in demand caused by a large NGS customer. Read ...

Galleri is a multi-cancer early detection (MCED) or 'liquid biopsy' test that Grail says can spot signs of up to 50 different ...